Logo
x

Search

Subscribe Now

Eli Lilly

Eli Lilly Reports Detailed Results from the P-III (QWINT-2 & 5) Trials of Insulin Efsitora Alfa (Efsitora) for Type 1 & 2 Diabetes at EASD 2024

Eli Lilly Reports Detailed Results from the P-III (QWINT-2 & 5) Trials of Insulin Efsitora Alfa (Efsitora) for Type 1 & 2 Diabetes...

  • September 11, 2024
Eli Lilly Reports Topline Results from P-III (QWINT-1 and QWINT-3) Studies of Efsitora Alfa (Efsitora) for Type 2 Diabetes

Eli Lilly Reports Topline Results from P-III (QWINT-1 and QWINT-3) Studies of Efsitora Alfa (Efsitora) for Type 2 Diabetes

  • September 6, 2024
PharmaShots Weekly Snapshots (August 20 – August 23, 2024)

PharmaShots Weekly Snapshots (August 20 – August 23, 2024)

  • August 23, 2024
Eli Lilly Reports Topline Data from P-III (SURMOUNT-1) Trial of Tirzepatide to Treat Type 2 Diabetes

Eli Lilly Reports Topline Data from P-III (SURMOUNT-1) Trial of Tirzepatide to Treat Type 2 Diabetes

  • August 21, 2024
Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity

Eli Lilly Reports the P-III (SUMMIT) Trial Data of Tirzepatide to Treat Heart Failure with Preserved Ejection Fraction and Obesity

  • August 2, 2024
Eli Lilly to Acquire Morphic Holdings for an Aggregate of ~$3.2B

Eli Lilly to Acquire Morphic Holdings for an Aggregate of ~$3.2B

  • July 8, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.